Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Gains from Sales and Divestitures: 2019-2024

Historic Gains from Sales and Divestitures for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $22,326.

  • Fulcrum Therapeutics' Gains from Sales and Divestitures fell 12.64% to $19,505 in Q3 2025 from the same period last year, while for Sep 2025 it was $19,505, marking a year-over-year decrease of 12.64%. This contributed to the annual value of $22,326 for FY2024, which is 23.05% up from last year.
  • Per Fulcrum Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $22,326 for FY2024, which was up 23.05% from $18,144 recorded in FY2023.
  • Fulcrum Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $291,789 during FY2020, with a 5-year trough of $10,174 in FY2022.
  • For the 3-year period, Fulcrum Therapeutics' Gains from Sales and Divestitures averaged around $16,881, with its median value being $18,144 (2023).
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 85.43% in 2022, then soared by 78.34% in 2023.
  • Over the past 5 years, Fulcrum Therapeutics' Gains from Sales and Divestitures (Yearly) stood at $291,789 in 2020, then slumped by 76.07% to $69,833 in 2021, then tumbled by 85.43% to $10,174 in 2022, then soared by 78.34% to $18,144 in 2023, then climbed by 23.05% to $22,326 in 2024.